Literature DB >> 1833311

Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis.

M Gruschwitz1, N Sepp, H Kofler, G Wick.   

Abstract

Expression of class II major histocompatibility complex (MHC) antigens on normally negative cell types may convert them into effective antigen-presenting cells. It was therefore of special interest to elucidate whether the main cell populations involved in progressive systemic sclerosis (PSS) express class II antigens on their surfaces and participate in the initiation and/or perpetuation of a cellular immune response in the connective tissue. Immunofluorescence studies on frozen skin sections of scleroderma patients using double-staining techniques revealed a pronounced dermal mononuclear cellular infiltrate with signs of activation manifested by expression of MHC class II antigens in the acute phase of the disease. Most endothelial cells of the papillary and deeper dermal vessels were class II-positive as seen in other inflammatory dermatoses. Moreover, class II antigen-positive fibroblasts were found, especially in the deeper dermis within infiltrated areas around blood vessels. MHC class II molecules were also detected in higher density and on increased numbers of perivascular dermal dendrocytes. On all cell types, HLA-DP was much less frequently expressed than HLA-DR, but more frequent than HLA-DQ. However, in the chronic phase of the disease, with reduced inflammation and increasing sclerosis, MHC class II antigen expression on dermal fibroblasts was again diminished or even absent, as seen in normal and non-PSS inflammatory control biopsies and clinically unaffected skin of scleroderma patients in the acute inflammatory disease stage. Our data speak against a primary expression of class II molecules on PSS-fibroblasts. It seems more likely that Ia-antigens on fibroblasts and an increase of MHC class II positive dermal dendrocytes are induced in an early stage of the disease, i.e., after the influx of the mononuclear infiltrate, most probably by mediators released from these cells. Since an enhanced transcription rate of collagen genes in fibroblasts surrounded by infiltrating cells has been described, this early expression of class II MHC antigens does not seem to play a central role in the induction phase, but rather, may be important in the perpetuation of fibrotic processes in scleroderma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833311     DOI: 10.1016/S0171-2985(11)80660-1

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  5 in total

1.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

2.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

3.  Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.

Authors:  H Fujii; M Hasegawa; K Takehara; N Mukaida; S Sato
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.

Authors:  M Hasegawa; S Sato; T Echigo; Y Hamaguchi; M Yasui; K Takehara
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

5.  Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study.

Authors:  Minoru Hasegawa; Yoshihide Asano; Hirahito Endo; Manabu Fujimoto; Daisuke Goto; Hironobu Ihn; Katsumi Inoue; Osamu Ishikawa; Yasushi Kawaguchi; Masataka Kuwana; Fumihide Ogawa; Hiroki Takahashi; Sumiaki Tanaka; Shinichi Sato; Kazuhiko Takehara
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.